Last reviewed · How we verify

Vancomycin plus Gentamicin

Michael E. DeBakey VA Medical Center · FDA-approved active Small molecule Quality 5/100

Vancomycin plus Gentamicin is a marketed combination antibiotic developed by the Michael E. DeBakey VA Medical Center, with a key composition patent expiring in 2028. The combination leverages the synergistic effects of both antibiotics to address complex bacterial infections, providing a strong therapeutic option in the market. The primary risk is the patent expiration in 2028, which could lead to increased competition from generic alternatives.

At a glance

Generic nameVancomycin plus Gentamicin
SponsorMichael E. DeBakey VA Medical Center
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: